Article: New Antidepressant Fares Well in Eli Lilly's Latest Clinical Trials.

By Jeff Swiatek, The Indianapolis Star Knight Ridder/Tribune Business News

Nov. 20--A year or less from hitting the market, Eli Lilly and Co.'s replacement for Prozac outperformed potential rival Paxil in the latest Lilly-sponsored patient tests.

Lilly said its drug duloxetine reduced symptoms of depression better than Paxil, the GlaxoSmithKline drug that ranked as the second most-prescribed antidepressant last year.

Based on its performance in a range of tests, "duloxetine may become a potent first-line antidepressant therapy," said Dr. John H. Greist, clinical professor of psychiatry at the University of Wisconsin Medical School.

...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!